|
Patent landscape, scope, and claims: |
US Patent 11,738,018 Landscape: What the Claims Cover for Relapsed/Refractory AML With IDH1 R132 Mutations and How Broad the Patent Estate Is
US Patent 11,738,018 is a method-of-treatment patent for relapsed/refractory acute myeloid leukemia (AML) in adults with an IDH1 mutation “susceptible to an IDH inhibitor,” detected by an FDA-approved test. The claims are anchored to a specific IDH1 inhibitor referred to as “Compound 1” dosed at 150 mg twice daily (total 300 mg/day) as single-agent oral therapy, with additional claim narrowing around (i) the IDH1 amino-acid substitutions (R132 set), (ii) optional co-mutations, and (iii) detailed eligibility criteria typical of clinical protocols (ECOG, organ function thresholds, QTcF).
What is the scope of US Patent 11,738,018 claims for AML patients with IDH1 mutations susceptible to IDH inhibitors?
Core claim theme: treating adult R/R AML via oral IDH1 inhibition in patients defined by (1) mutation status from an FDA-approved test and (2) an IDH1 inhibitor at a specific dosing regimen.
Claim 1: What is claimed, in plain scope terms
- Patient population: adults with relapsed or refractory AML.
- Biomarker gate: an IDH1 mutation susceptible to an IDH inhibitor as detected by an FDA-approved test.
- Treatment modality: administer “Compound 1” (the IDH1 inhibitor).
- Dose and schedule: 150 mg twice daily (oral administration is explicitly stated in dependent claims).
- Use conditions: single agent until disease progression or unacceptable toxicity.
Claim 14: Is oral administration required?
Claim 14 depends conceptually on Claim 1 but explicitly tightens administration terms:
- Oral dosing is expressly recited.
- “With or without food” is allowed.
- Single agent remains.
Claim 19 and dependent claim sets: How do co-mutations expand or narrow coverage?
- Claim 19 adds the presence of one or more co-mutations from a large panel while still requiring:
- adult R/R AML,
- susceptible IDH1 mutation by FDA-approved test,
- Compound 1 at 150 mg BID as single agent oral therapy.
Key structural point: the co-mutation panel is used as a patient qualifier, not as a combination therapy requirement. The claims still read on Compound 1 as the administered agent, with the co-mutation being a condition of patent coverage.
Which IDH1 mutation variants are covered by US Patent 11,738,018?
The claims are structured around IDH1 substitutions in the R132 region.
Covered “susceptible IDH1 mutation” lists in dependent claims
- R132G, R132S, R132L (Claim 2)
- R132H, R132C (Claim 3)
- Broader R132 set including R132C, R132H, R132G, R132S, R132L (Claim 15)
Scope implication for design-around
A party trying to avoid infringement would focus on whether:
- the patient population excludes these specific variants, and/or
- “susceptible to an IDH inhibitor” could be interpreted in a way that excludes certain IDH1 variants, although the claims already enumerate R132 substitutions in dependent claims.
Does the patent cover AML with specific co-mutation profiles (DNMT3A/NPM1/FLT3 etc.)?
The claim architecture uses co-mutations as optional qualifiers.
Co-mutation panels recited
The patent recites multiple co-mutation groupings that map to common AML genomic alterations. Examples include:
Large panel (repeated across multiple dependent claims):
DNMT3A, NPM1, SRSF2, NRAS, RUNX1, ASXL1, STAG2, TET2, SMC1A, SF3B1, U2AF1, PHF6, JAK2, MPL, NF1, ASXL2, BCOR, EED, WT1, CBL, CSF3R, ETNK1, PTPN11, ATM, TP53.
Smaller panel (appearing in dependent claims):
FLT3, NPM1, CEBPA, TP53.
Another smaller panel that includes IDH2 in addition to the FLT3/NPM1/CEBPA/TP53 set:
FLT3, NPM1, CEBPA, TP53, IDH2.
Claim hierarchy impact
- If the independent claim is broad (Claim 1 or 14), a generic entrant would face infringement risk for the IDH1-defined patient population even without the co-mutation qualifiers.
- The co-mutation dependent claims matter most for:
- strengthening infringement positions when specific genomic profiles are treated in registrational or real-world use, and
- narrowing the asserted claim set during litigation to match treated cohorts.
What eligibility criteria are required in US Patent 11,738,018 (ECOG, organ function, QTcF)?
The patent adds typical trial entry constraints that, when asserted, can materially narrow scope to patients meeting those clinical thresholds.
Inclusion criteria recited in dependent claims (representative set in Claims 13/18/20)
- ECOG performance status: 0 to 2.
- No prior solid organ allograft.
- Liver function:
- bilirubin ≤ 2× ULN (≤ 3× ULN in Gilbert syndrome),
- AST, ALT, ALP ≤ 3× ULN (with a variant wording in one claim set).
- Renal function:
- serum creatinine ≤ 1.5× ULN or
- calculated creatinine clearance ≥ 50 mL/min.
- Recovery from non-hematologic toxic effects of prior treatment: Grade ≤ 1 or baseline per NCI CTCAE, excluding infertility, alopecia, or Grade 1 neuropathy.
- Cardiac QTcF: baseline QTcF ≤ 450 ms (average of triplicate ECGs) for patients without bundle branch block (BBB).
Practical litigation relevance
These criteria often become a focal point where defendants argue:
- real-world patient populations do not meet the claim thresholds, or
- labeling-driven inclusion/exclusion differs from the patent’s eligibility language.
How is the dosing regimen defined and what dosing-related design-around options exist?
Dose and schedule anchor
- 150 mg twice daily.
- Total daily dose: 300 mg/day.
- Single agent use.
- Duration: until progression or unacceptable toxicity.
Food effect
- Claim 14 allows with or without food.
Design-around logic
- A straightforward evasion would require avoiding literal infringement by changing dose/schedule, route, or single-agent status. But method-of-use claims can still be asserted under equivalents depending on claim construction standards.
- If an accused product is used in practice in a regimen that matches the claim, the dosing language becomes a high-value infringement lever.
Does US 11,738,018 read on combination therapy or only single-agent use?
The claims repeatedly recite single agent. They do not claim co-administration of standard backbones (e.g., hypomethylating agents, cytarabine, venetoclax) as required steps. Coverage is therefore:
- aligned to IDH1 inhibitor monotherapy,
- with the co-mutation panels acting as stratifiers rather than add-on therapeutic components.
What parts of the claims are likely to be argued as “key limitations” in enforcement?
Highest-friction limitations
- FDA-approved test detection requirement
The patient must be identified as having an IDH1 mutation “susceptible to an IDH inhibitor” as detected by an FDA-approved test. This can be attacked on:
- whether the test used is FDA-approved for that intended claim,
- how “susceptible” is determined in the diagnostic context.
- Specific IDH1 R132 substitution lists (in dependent claims)
- Compound 1 at 150 mg BID
- Single-agent monotherapy
- Eligibility criteria
These can be used to argue non-overlap if real-world treated patients do not meet the thresholds.
What is the likely patent estate coverage for US 11,738,018 across other claim scopes (formulation, methods, combination, other mutations)?
From the claim text provided, US 11,738,018 is confined to:
- method-of-treatment,
- IDH1 inhibitor monotherapy,
- adult R/R AML,
- mutation-defined populations and, in dependent claims, trial eligibility thresholds.
What is not shown in the provided claims: formulation patents, manufacturing method patents, broad genus claims covering other AML stages (treatment-naïve), or combination therapy regimens.
How strong is the patent estate likely to be for competitors seeking an AML IDH1 inhibitor entry?
Strength here is primarily about claim fit versus real-world and label-driven practice.
Where the claims have strong enforcement leverage
- If the leading IDH1 inhibitor’s commercial and clinical use matches:
- 150 mg BID,
- oral dosing,
- single-agent therapy,
- and treatment of adults with R/R AML bearing R132 IDH1 mutations by FDA-approved testing,
then US 11,738,018 becomes a “tight match” method patent.
Where leverage weakens
- If accused use deviates on:
- dosing (not 150 mg BID),
- route (not oral),
- monotherapy (combination backbone changes “single agent” reading),
- testing (non FDA-approved assay used clinically),
- or patient eligibility thresholds (real-world populations broader than trial constraints),
the claim limitations can be used to narrow or dismiss infringement theories.
What generic entry risks exist for an IDH1 inhibitor that could be used off-label or differently in R/R AML?
Risk profile by claim feature
- High risk: same drug class, same mechanism, but used as Compound 1 at 150 mg BID oral single agent in patients defined by FDA-approved diagnostic testing.
- Lower risk but still litigation-prone: use in combination, different dosing, or different patient inclusion criteria can create non-infringement arguments, but the patent can still capture patient subsets treated under compliant conditions.
Method-of-use bottleneck
Even if a generic obtains approval on a product basis, method-of-use claims can restrict marketing for certain indications until patent issues resolve (depending on the regulatory and listing framework).
How does the claim scope compare with typical IDH1 inhibitor AML patents (method-of-use breadth)?
US 11,738,018 is not framed as:
- a broad “any AML with IDH1 mutation” claim across all R/R versus earlier lines,
- or a generic “administer an IDH1 inhibitor” claim without dosing and test qualifiers.
It is instead framed as:
- a dose-defined, route-defined, monotherapy method,
- with explicit diagnostic framing and, in dependent claims, molecular subtype and clinical eligibility.
That structure generally increases “fit” for enforcement but also increases the number of limitations a challenger can try to break.
What is the “US exclusivity” versus “patent exclusivity” exposure for IDH1 AML therapy based on this patent?
Based on claim structure alone, US 11,738,018 affects the ability to lawfully practice the claimed method in the US. The practical takeaway is:
- generic or biosimilar-style entry depends not just on product approval, but on label, diagnostic test usage, and how the method is practiced relative to the claim steps.
- This is a classic method-of-use containment mechanism rather than a manufacturing/formulation lock.
Key takeaways
- US 11,738,018 claims method-of-treatment for adult relapsed/refractory AML defined by IDH1 mutation susceptible to an IDH inhibitor, as detected by an FDA-approved test.
- The dosing core is Compound 1 at 150 mg twice daily, oral and single-agent, continued until progression or unacceptable toxicity (as recited in dependent claim language).
- Dependent claims narrow the IDH1 mutation set to R132C/R132H/R132G/R132S/R132L and add co-mutation qualifiers (including common AML alterations and sometimes IDH2).
- Dependent claims include clinical eligibility thresholds (ECOG 0-2, organ function limits, QTcF ≤ 450 ms, and other trial-style criteria), which can materially narrow infringement coverage to patient subsets matching the claim.
- The patent is likely strongest when real-world use mirrors the claim’s test-based selection, monotherapy regimen, and 150 mg BID dosing in the specified R/R AML setting.
FAQs
1) What patient biomarker gating is required by US 11,738,018?
Patients must have an IDH1 mutation susceptible to an IDH inhibitor as detected by an FDA-approved test.
2) Is oral administration required in all claims of US 11,738,018?
Oral administration is explicitly recited in the method claim set that corresponds to Claim 14 and its dependencies.
3) Which IDH1 mutations are explicitly listed in dependent claims?
R132 substitutions listed include R132G, R132S, R132L, R132H, and R132C.
4) Does the patent require co-mutations for infringement?
No independent coverage in the provided claim set requires co-mutations; co-mutations appear in dependent claims, including large and smaller AML genomic panels.
5) Can combination therapy avoid infringement of US 11,738,018?
The claims expressly recite single agent; combination use can be a non-infringement argument if it breaks the “single agent” limitation, depending on claim construction and the accused regimen.
References
- US Patent 11,738,018 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
